Login to Your Account



Amgen, Abgenix Expanding Panitumumab Phase III Work

By Karen Pihl-Carey


Thursday, April 28, 2005
Taking a different approach with their metastatic colorectal cancer drug panitumumab, Amgen Inc. and Abgenix Inc. started another Phase III trial of the therapy, this time as a first-line treatment administered with bevacizumab and chemotherapy. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription